Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 01, 2024 10:17 ET | Source: Research and Markets

Global Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Report 2024: Gamma Delta T Cell Therapy Poised to Revolutionize Cancer Treatment by 2030, Surpassing 30 Therapies in Clinical Trials

Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's...
October 26, 2022 08:30 ET | Source: Brain Cancer Canada

Canadian Brain Cancer Patients Treated Unequally: Brain Cancer Canada

TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...
June 08, 2022 04:43 ET | Source: Research and Markets

Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment

Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...
March 17, 2022 11:45 ET | Source: FACT.MR

Surgery Treatment of Glioblastoma Multiforme to Register a Double-digit Growth in next ten years, Fact.MR

ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- The Glioblastoma Multiforme Treatment Market revenues were estimated at US$ 2.6 Bn in 2021 and is anticipated to grow at a CAGR of 10.1% from...
December 31, 2021 04:53 ET | Source: Research and Markets

Investigation Report on China's Temozolomide Market 2021-2025 Featuring Merck Sharp & Dohme, Jiangsu Tasly Diyi Pharma, Beijing Shuanglu Pharma, Schering-Plough, Jiangsu Hengrui Medicine Co

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Temozolomide Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The sales value of...
February 13, 2019 09:15 ET | Source: Oncotelic Inc

Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma

Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...